May 12, 2023 06:41 PM EDTUpdated May 16, 06:54 PM
R&D

Proxy ad­vis­er ISS sup­ports on­ly one of Ic­ah­n's can­di­dates for Il­lu­mi­na board

Jared Whitlock

Features Editor

A sec­ond proxy ad­vis­er firm is­sued a neg­a­tive opin­ion of Il­lu­mi­na’s gov­er­nance in the midst of its fight with in­vestor Carl Ic­ahn, an­oth­er blow to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times